American Heart Journal
Volume 157, Issue 1 , Pages 111-117.e2 , January 2009

Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines

  • Amit Sachdeva, MD

      Affiliations

    • Department of Medicine, UCLA Medical Center, Los Angeles, CA
    • ,
  • Christopher P. Cannon, MD

      Affiliations

    • Brigham and Women's Hospital & Harvard Medical School, Boston, MA
    • ,
  • Prakash C. Deedwania, MD

      Affiliations

    • Department of Cardiology, VA Medical Center/UCSF School of Medicine, San Francisco, CA
    • ,
  • Kenneth A. LaBresh, MD

      Affiliations

    • Masspro, Waltham, MA
    • ,
  • Sidney C. Smith Jr, MD

      Affiliations

    • University of North Carolina School of Medicine, Chapel Hill, NC
    • ,
  • David Dai, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Adrian Hernandez, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • Department of Medicine, UCLA Medical Center, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Gregg C. Fonarow, MD, Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, 10833 LeConte Avenue, Room 47-123 CHS, Los Angeles, CA 90095-1679.
    • ,
  • on behalf of the GWTG Steering Committee and Hospitals

Received 9 May 2008 ,Accepted 6 August 2008.

References 

  1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report.. Circulation. 2002;106:3143–3421
  2. Grundy SM, Cleeman JI, Merz CNB, et al. for the Coordinating Committee of the National Cholesterol Education Program and Endorsed by the National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, and American Heart Association Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  3. Carroll MD, Lacher DA, Sorlie PD, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA. 2005;294:1773–1781
  4. LaBresh KA, Ellrodt AG, Gliklich R, et al. Get With The Guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med. 2004;164:203–209
  5. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  7. Castelli W. Cholesterol and lipids in the risk of coronary artery disease—the Framingham Heart Study. Can J Cardiol. 1988;4(Suppl A):5a–10a
  8. Ansell BJ, Watson KE, Fogelman AM, et al. High-density lipoprotein function: recent advances. J Am Coll Cardiol. 2005;46:1792–1798
  9. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428
  10. Gregg EW, Cheng YJ, Cadwell BJ, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005;293:1868–1874
  11. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations. Am J Cardiol. 2005;96:556–563
  12. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–467
  13. Dodds C, Mills GL. Influence of myocardial infarction on plasma-lipoprotein concentration. Lancet. 1959;1:1160–1163
  14. Pfohl M, Schreiber I, Liebich HM, et al. Upregulation of cholesterol synthesis after acute myocardial infarction—is cholesterol a positive acute phase reactant?. Atherosclerosis. 1999;142:389–393
  15. Pitt B, Loscalzo , Ycas J, et al. Lipid levels after acute coronary syndromes. J Am Coll Cardiol. 2008;51:1440–1445

 The Get With The Guidelines Program is supported by the American Heart Association (Dallas, TX) in part through an unrestricted education grant from the Merck Schering Plough Partnership (North Wales, PA) who did not participate in the design, analysis, preparation, review, or approval of this article.

 Financial disclosures: Amit Sachdeva, MD (none); Christopher P. Cannon, MD (grants: Accumetrics [San Diego, CA], AstraZeneca [Wilmington, DE], Bristol-Myers Squibb [New York, NY], GlaxoSmithKline [Philadelphia, PA], Merck [Whitehouse Station, NJ], Sanofi-Aventis [Bridgewater, NJ], Schering Plough [Kenilworth, NJ]); Prakash C. Deedwania, MD (consultant of AstraZeneca and Pfizer [New York, NY]); Kenneth A. LaBresh, MD (none); Sidney C. Smith, Jr., MD (none); David Dai, PhD (employee of Duke Clinical Research Institute [Durham, NC]); Adrian Hernandez, MD (none); Gregg C. Fonarow, MD (research from Pfizer and GlaxoSmithKline; consultant and honorarium from Abbott, AstraZeneca, GlaxoSmithKline, Merck, Pfizer, and Schering Plough; and chair of the Get With the Guidelines Steering Committee).

 Dr. Todd D. Miller served as guest editor for this manuscript.

PII: S0002-8703(08)00717-5

doi: 10.1016/j.ahj.2008.08.010

American Heart Journal
Volume 157, Issue 1 , Pages 111-117.e2 , January 2009

Article Tools

* Image Usage & Resolution